Gilead Sciences Inc (GILD.OQ)

GILD.OQ on NASDAQ Stock Exchange Global Select Market

92.85USD
11:28am EDT
Price Change (% chg)

$1.39 (+1.52%)
Prev Close
$91.46
Open
$92.00
Day's High
$93.10
Day's Low
$91.60
Volume
1,804,789
Avg. Vol
3,815,867
52-wk High
$93.10
52-wk Low
$55.96

GILD.OQ

Chart for GILD.OQ

About

Gilead Sciences, Inc. (Gilead) is a research-based biopharmaceutical company that discovers, develops and commercializes medicines. Gilead’s primary areas of focus include human immunodeficiency virus (HIV)/AIDS, liver diseases, such as hepatitis B and C and cardiovascular/metabolic and respiratory conditions. The Company has... (more)

Overall

Beta: 0.72
Market Cap (Mil.): $139,571.91
Shares Outstanding (Mil.): 1,526.04
Dividend: --
Yield (%): --

Financials

  GILD.OQ Industry Sector
P/E (TTM): 20.55 35.65 36.07
EPS (TTM): 4.45 -- --
ROI: 35.11 18.91 18.18
ROE: 54.23 19.67 19.05
Search Stocks

A mixed quarter for bets on U.S. stock volatility

NEW YORK - With some of Wall Street's more volatile names set to report in the next couple of days, traders who bet on big swings in shares are hoping to see moves more like Facebook than Netflix.

10:39am EDT

Europe backs new leukemia drugs from J&J and Gilead

LONDON - Two new leukemia drugs from Johnson & Johnson and Gilead Sciences have been recommended for approval by European regulators, paving the way for formal approval in a couple of months.

25 Jul 2014

Europe backs new leukaemia drugs from J&J and Gilead

LONDON, July 25 - Two new leukaemia drugs from Johnson & Johnson and Gilead Sciences have been recommended for approval by European regulators, paving the way for formal approval in a couple of months.

25 Jul 2014

BRIEF-EU medicines agency backs new drugs from Novo Nordisk, J&J, Gilead

July 25 - The European Medicines Agency: * EU medicines agency says recommends Novo Nordisk diabetes

25 Jul 2014

Gilead hepatitis C drug Sovaldi racks up $3.5 billion in quarter

- Gilead Sciences Inc said on Wednesday that its new hepatitis C drug Sovaldi had sales of $3.5 billion in the second quarter, demonstrating that the furor over its price has not curtailed early use.

23 Jul 2014

UPDATE 2-Gilead hepatitis C drug Sovaldi racks up $3.5 bln in quarter

(Adds insurance group, company, analyst comment, cancer drug approval)

23 Jul 2014

Sales of Gilead hepatitis C drug Sovaldi soar in 2nd quarter

July 23 - Gilead Sciences Inc said on Wednesday that its new hepatitis C drug Sovaldi had sales of $3.5 billion in the second quarter, crushing Wall Street estimates and demonstrating that the furor over its price has not curtailed early use.

23 Jul 2014

U.S. FDA approves Gilead blood cancer drug Zydelig

- The U.S. Food and Drug Administration said on Wednesday it has approved Gilead Sciences Inc's Zydelig, a drug to treat three types of blood cancer.

23 Jul 2014

U.S. FDA approves Gilead blood cancer drug Zydelig

- The U.S. Food and Drug Administration said on Wednesday it has approved Gilead Sciences Inc's Zydelig, a drug to treat three types of blood cancer.

23 Jul 2014

U.S. FDA approves Gilead blood cancer drug Zydelig

- The U.S. Food and Drug Administration said on Wednesday it has approved Gilead Sciences Inc's Zydelig, a drug to treat three types of blood cancer.

23 Jul 2014

Competitors

  Price Change
Pfizer Inc. (PFE.N) $30.10 +0.00
Novartis AG (NOVN.VX) CHF80.00 +0.60
Merck & Co., Inc. (MRK.N) $58.84 +0.87
Roche Holding Ltd. (ROG.VX) CHF265.80 +0.30
Abbott Laboratories (ABT.N) $42.70 -0.23
AstraZeneca plc (AZN.L) 4,322.50p -38.50
GlaxoSmithKline plc (GSK.L) 1,419.00p +4.50
Bristol-Myers Squibb Co (BMY.N) $50.66 +0.86
Bristol-Myers Squibb Co (BMYMP.PK) $829.72 -58.28
Shire PLC (SHP.L) 4,915.00p -27.00

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks